Europe
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.
CEO Emma Walmsley’s vision includes a projected $46 billion in annual sales from the stand-alone pharma company by 2031 and more than 10% operating profit over the next five years.
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
Biopharma and life sciences companies from across the globe provide updates on their business operations and pipelines.
This week, the German drug company announced that it is closing the doors to its ‘innovation hub’ in Mission Bay.
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
PRESS RELEASES